New Drug Approvals 2022

New Drug Approvals 2022

The following drugs have recently been approved by the FDA.

Tecvayli (teclistamab-cqyv) Injection

Date of Approval: October 25, 2022

Treatment for: Multiple Myeloma

Tecvayli (teclistamab-cqyv) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.

Imjudo (tremelimumab-actl) Injection

Date of Approval: October 21, 2022

Treatment for: Hepatocellular Carcinoma

Imjudo (tremelimumab-actl) is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated in combination with durvalumab (Imfinzi) for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).

Furoscix (furosemide) Injection

Date of Approval: October 7, 2022

Treatment for: Heart Failure

Furoscix (furosemide) is a loop diuretic indicated for the at-home treatment of congestion due to fluid overload in adults with NYHA Class II/III chronic heart failure.


Suggested readings:

Related Blogs